clinical trial · NCT07020923
Monthly Dosing of Atacicept in IgAN
IgA Nephropathy (IgAN)Berger DiseaseAtacicept
brief summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
started
May 29, 2025
primary completion
Sep 1, 2026
completion
Sep 1, 2027
last updated
Apr 13, 2026
detailed description
This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing.
official title
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol